Key Insights

Highlights

Treatment Research

2 treatments under study, led by 212lead Pentixather

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Early Phase 1 (1)

Trial Status

Not Yet Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05557708Early Phase 1Not Yet RecruitingPrimary

A Safety Study of 212Pb-Pentixather Radioligand Therapy

Showing all 1 trials

Research Network

Common Treatments

  • 212lead Pentixather1
  • 203lead Pentixather Spectct1

Active Sponsors

  • National Cancer Institute (NCI)1
  • Holden Comprehensive Cancer Center1
  • National Institutes of Health (NIH)1
  • Yusuf Menda1

Top Investigators

Related Conditions

  • Carcinoma Smallcell Lung1
  • Neuroendocrine Tumor Of The Lung1

Activity Timeline